Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy | Journal of Hematology Oncology BioMed Central Review Open Access Targeting tumorigenesis development and use of mTOR inhibitors in cancer therapy RuiRong Yuan Andrea Kay William J Berg and David Lebwohl Address Novartis Oncology Florham Park NJ USA Email RuiRong Yuan - yuanru@ Andrea William J Berg - David Lebwohl - Corresponding author Published 27 October 2009 Received 14 August 2009 Journal of Hematology Oncology 2009 2 45 doi 1756-8722-2-45 Accepted 27 October 2009 This article is available from http content 2 1 45 2009 Yuan et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract The mammalian target of rapamycin mTOR is an intracellular serine threonine protein kinase positioned at a central point in a variety of cellular signaling cascades. The established involvement of mTOR activity in the cellular processes that contribute to the development and progression of cancer has identified mTOR as a major link in tumorigenesis. Consequently inhibitors of mTOR including temsirolimus everolimus and ridaforolimus formerly deforolimus have been developed and assessed for their safety and efficacy in patients with cancer. Temsirolimus is an intravenously administered agent approved by the US Food and Drug Administration FDA and the European Medicines Agency EMEA for the treatment of advanced renal cell carcinoma RCC . Everolimus is an oral agent that has recently obtained US FDA and EMEA approval for the treatment of advanced RCC after failure of treatment with sunitinib or sorafenib. Ridaforolimus is not yet approved for any indication. The use of mTOR inhibitors either alone or in combination with other .
